An analysis of real-world data showed that Tepezza helped improve visual acuity in patients with dysthyroid optic neuropathy, according to a press release.
“We know how devastating thyroid eye disease can be for patients, and the risk of blindness in those with dysthyroid optic neuropathy is one of the most worrisome complications, especially when traditional therapies fail,” study author Madhura A. Tamhankar, MD, said in the release. “These data are encouraging for physicians looking for an option to treat patients at the highest risk of losing their sight and provide